CO2024001017A2 - Compuestos terapéuticos y procedimientos - Google Patents
Compuestos terapéuticos y procedimientosInfo
- Publication number
- CO2024001017A2 CO2024001017A2 CONC2024/0001017A CO2024001017A CO2024001017A2 CO 2024001017 A2 CO2024001017 A2 CO 2024001017A2 CO 2024001017 A CO2024001017 A CO 2024001017A CO 2024001017 A2 CO2024001017 A2 CO 2024001017A2
- Authority
- CO
- Colombia
- Prior art keywords
- procedures
- therapeutic compounds
- prodrug
- compound
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000012435 Phosphofructokinase-1 Human genes 0.000 abstract 2
- 108010022684 Phosphofructokinase-1 Proteins 0.000 abstract 2
- 230000002414 glycolytic effect Effects 0.000 abstract 2
- 230000002440 hepatic effect Effects 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222288P | 2021-07-15 | 2021-07-15 | |
| PCT/US2022/036829 WO2023287793A1 (en) | 2021-07-15 | 2022-07-12 | Therapeutic compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001017A2 true CO2024001017A2 (es) | 2024-03-07 |
Family
ID=84919638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001017A CO2024001017A2 (es) | 2021-07-15 | 2024-01-30 | Compuestos terapéuticos y procedimientos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12006331B2 (https=) |
| EP (1) | EP4370130A4 (https=) |
| JP (1) | JP2024527604A (https=) |
| KR (1) | KR20240036571A (https=) |
| CN (1) | CN117642170A (https=) |
| AR (1) | AR126470A1 (https=) |
| AU (1) | AU2022309856A1 (https=) |
| CA (1) | CA3226225A1 (https=) |
| CL (1) | CL2024000114A1 (https=) |
| CO (1) | CO2024001017A2 (https=) |
| CR (1) | CR20240016A (https=) |
| IL (1) | IL309878A (https=) |
| MX (1) | MX2024000610A (https=) |
| PE (1) | PE20240776A1 (https=) |
| TW (1) | TW202317586A (https=) |
| WO (1) | WO2023287793A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117642170A (zh) | 2021-07-15 | 2024-03-01 | 基因泰克公司 | 治疗性化合物及方法 |
| WO2025082533A1 (zh) * | 2023-10-21 | 2025-04-24 | 上海轶诺药业有限公司 | 一种稠环化合物及其制备和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003508401A (ja) * | 1999-08-27 | 2003-03-04 | アボット・ラボラトリーズ | Ｃｏｘ−２阻害薬として有用なスルホニルフェニルピラゾール化合物 |
| JP2003510280A (ja) * | 1999-09-27 | 2003-03-18 | アメリカン・サイアナミド・カンパニー | バソプレッシンアゴニスト処方および製法 |
| AR039475A1 (es) * | 2002-05-01 | 2005-02-23 | Wyeth Corp | 6-alquiliden-penems triciclicos como inhibidores de beta-lactamasa |
| US20070232582A1 (en) | 2004-04-28 | 2007-10-04 | Wyeth Holdings Corporation | 4-substituted or unsubtituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors |
| CA3103432A1 (en) * | 2018-06-27 | 2020-01-02 | Children's Medical Center Corporation | Compounds for inhibition of inflammation |
| EP3833345B1 (en) | 2018-08-07 | 2024-07-17 | Kemijski Institut | Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing lactate generation by cancer cells |
| CN117642170A (zh) | 2021-07-15 | 2024-03-01 | 基因泰克公司 | 治疗性化合物及方法 |
-
2022
- 2022-07-12 CN CN202280049669.2A patent/CN117642170A/zh active Pending
- 2022-07-12 CR CR20240016A patent/CR20240016A/es unknown
- 2022-07-12 IL IL309878A patent/IL309878A/en unknown
- 2022-07-12 AU AU2022309856A patent/AU2022309856A1/en active Pending
- 2022-07-12 WO PCT/US2022/036829 patent/WO2023287793A1/en not_active Ceased
- 2022-07-12 US US17/862,963 patent/US12006331B2/en active Active
- 2022-07-12 MX MX2024000610A patent/MX2024000610A/es unknown
- 2022-07-12 JP JP2024501696A patent/JP2024527604A/ja active Pending
- 2022-07-12 CA CA3226225A patent/CA3226225A1/en active Pending
- 2022-07-12 PE PE2024000068A patent/PE20240776A1/es unknown
- 2022-07-12 EP EP22842759.7A patent/EP4370130A4/en active Pending
- 2022-07-12 KR KR1020247002069A patent/KR20240036571A/ko active Pending
- 2022-07-15 TW TW111126584A patent/TW202317586A/zh unknown
- 2022-07-15 AR ARP220101868A patent/AR126470A1/es unknown
-
2024
- 2024-01-12 CL CL2024000114A patent/CL2024000114A1/es unknown
- 2024-01-30 CO CONC2024/0001017A patent/CO2024001017A2/es unknown
- 2024-05-08 US US18/657,963 patent/US12459957B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240036571A (ko) | 2024-03-20 |
| EP4370130A4 (en) | 2025-06-11 |
| WO2023287793A1 (en) | 2023-01-19 |
| JP2024527604A (ja) | 2024-07-25 |
| US12459957B2 (en) | 2025-11-04 |
| AU2022309856A1 (en) | 2024-01-18 |
| US12006331B2 (en) | 2024-06-11 |
| US20250109142A1 (en) | 2025-04-03 |
| US20230119740A1 (en) | 2023-04-20 |
| CL2024000114A1 (es) | 2024-08-02 |
| CN117642170A (zh) | 2024-03-01 |
| MX2024000610A (es) | 2024-02-02 |
| TW202317586A (zh) | 2023-05-01 |
| AR126470A1 (es) | 2023-10-11 |
| PE20240776A1 (es) | 2024-04-17 |
| IL309878A (en) | 2024-03-01 |
| EP4370130A1 (en) | 2024-05-22 |
| CA3226225A1 (en) | 2023-01-19 |
| CR20240016A (es) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| MX2023006145A (es) | Inhibidores de prmt5 novedosos. | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2024001017A2 (es) | Compuestos terapéuticos y procedimientos | |
| UY31072A1 (es) | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido | |
| CL2011002990A1 (es) | Compuestos derivados de bifenilo, inhibidores de endopeptidasa neutra (nep); composición farmacéutica; combinación farmacéutica; uso del compuesto para tratar un trastorno o enfermedad tal como la hipertensión, insuficiencia cardiaca, insuficiencia renal, glaucoma, trastornos reproductivos, entre otros. | |
| ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
| CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
| CL2021003342A1 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. | |
| DOP2024000102A (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CR20250267A (es) | Inhibidores de polq | |
| MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. | |
| CL2024001470A1 (es) | Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica | |
| MX2021009206A (es) | Terapias contra el cancer. | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| MX2023012958A (es) | Compuestos y metodos anticonceptivos. | |
| BR112013012665A2 (pt) | composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica | |
| ECSP088237A (es) | Derivados de quinolina y uso como agentes antitumor | |
| AR133935A1 (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| AR132459A1 (es) | Inhibidores de kras de pirrolidina |